Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

NCT03784326 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage II Esophageal Adenocarcinoma AJCC v8
Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage III Esophageal Adenocarcinoma AJCC v8
Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8

Interventions

DRUG: Atezolizumab
PROCEDURE: Conventional Surgery
DRUG: Fluorouracil
DRUG: Oxaliplatin
DRUG: Tiragolumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]